Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data, GWU to Study Benefits of Using PGx to Dose Warfarin

NEW YORK (GenomeWeb News) — Clinical Data’s PGxHealth division will work with clinical researchers at George Washington University to study the effectiveness of using genomic testing to guide dosing decisions for the widely used anticoagulant warfarin, the company said yesterday.
 
The studies will use Clinical Data’s PGxPredict:Warfarin in a trial involving 80 post-surgical GWU patients to “evaluate the potential clinical, safety, and treatment-time benefits of using the genetic test to determine optimal warfarin dosing.”
 
Doctors at GWU’s Medical Faculty Associates Department of Orthopedic Surgery will conduct the study by using CD’s test to determine warfarin dosing in half of the subjects, the company said.  
 
If the program shows positive results, the company said GWU could incorporate the test into the clinic’s standard practices.
 
According to Clinical Data, the Clinical Pharmacology Subcommittee of the Food and Drug Administration’s Advisory Committee for Pharmaceutical Sciences said that “sufficient mechanistic and clinical evidence exists to use lower doses of warfarin for patients with genetic variations in CYP2C9 that lead to reduced activity and genotyping patients in the induction phase of warfarin therapy [which] would reduce adverse events and improve achievement of stable INR in patients with genetic variations in CYP2C9.”
 
Also, “sufficient mechanistic and clinical evidence exists to use lower doses of warfarin for patients with genetic variations in VKORC1 that lead to reduced VKORC1 activity and genotyping patients in the induction phase of warfarin therapy [which] would reduce adverse events and improve achievement of stable INR in patients with genetic variations in VKORC1.”

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more